FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org October 30, 2009 (10.1056/NEJMe0909664)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Anemia associated with chronic kidney disease and end-stage renal disease is due, in large part, to reduced production of renal erythropoietin and abnormalities in extracellular-fluid volume homeostasis.¹ Moreover, anemia and disordered salt and water handling, which usually manifest as hypertension, predict cardiovascular and renal outcomes in patients with chronic kidney disease.² The combination of early recognition and treatment to reduce increased blood pressure is known to improve outcomes. Thus, it is surprising, since highly effective therapies for anemia have been available for more than 20 years,³ that so little is known about whether the treatment of anemia has similar salutary . . . [Full Text of this Article]

Source Information

From the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital; and the University of Toronto — both in Toronto.

This article (10.1056/NEJMe0909664) was published on October 30, 2009, at NEJM.org.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.